Of the 10 NF-κB target genes up-regulated in all datasets, CXCL8 is potentially the most relevant clinically because high levels of interleukin-8 (IL-8) (the protein encoded by CXCL8) in the serum and the TME have been associated with a reduced clinical benefit from immune-checkpoint inhibitors across multiple cancer types (45, 46). Here, CXCL8 is linked to cancer.